Literature DB >> 18374152

Human pancreatic duct epithelial cell model for KRAS transformation.

Nikolina Radulovich1, Jia-ying Qian, Ming-Sound Tsao.   

Abstract

Mutations on the KRAS gene occur early during pancreatic duct cell carcinogenesis and have been identified in up to 90% of ductal adenocarcinoma. However, the functional role of KRAS mutations in the malignant transformation of normal pancreatic duct epithelial cells into cancer cells remains unknown. We have developed an in vitro model for KRAS transformation using near-normal HPV-16E6E7-immortalized human pancreatic ductal epithelial (HPDE-E6E7) cells. The expression of mutant KRAS(G12V) in HPDE cells by retroviral transduction resulted in weak tumorigenic transformation, with tumors formed in 50% of immune-deficient scid mice implanted by these KRAS-transformed cells. The model provides an opportunity to dissect further the molecular and cellular mechanisms associated with human pancreatic duct cell carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374152     DOI: 10.1016/S0076-6879(07)00401-6

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  19 in total

Review 1.  Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2010-11-01       Impact factor: 6.261

2.  Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.

Authors:  Sandrina Maertin; Jason M Elperin; Ethan Lotshaw; Matthias Sendler; Steven D Speakman; Kazuki Takakura; Benjamin M Reicher; Olga A Mareninova; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-07-13       Impact factor: 4.052

3.  KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Authors:  Angelina V Vaseva; Devon R Blake; Thomas S K Gilbert; Serina Ng; Galen Hostetter; Salma H Azam; Irem Ozkan-Dagliyan; Prson Gautam; Kirsten L Bryant; Kenneth H Pearce; Laura E Herring; Haiyong Han; Lee M Graves; Agnieszka K Witkiewicz; Erik S Knudsen; Chad V Pecot; Naim Rashid; Peter J Houghton; Krister Wennerberg; Adrienne D Cox; Channing J Der
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

4.  microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy.

Authors:  Jie Xiao; Feng Peng; Chao Yu; Min Wang; Xu Li; Zhipeng Li; Jianxin Jiang; Chengyi Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 5.  Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Authors:  Jing Li; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-03-03       Impact factor: 4.009

6.  Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution.

Authors:  Maria E Monberg; Heather Geiger; Jaewon J Lee; Roshan Sharma; Alexander Semaan; Vincent Bernard; Justin Wong; Fang Wang; Shaoheng Liang; Daniel B Swartzlander; Bret M Stephens; Matthew H G Katz; Ken Chen; Nicolas Robine; Paola A Guerrero; Anirban Maitra
Journal:  Nat Commun       Date:  2022-06-25       Impact factor: 17.694

7.  Characterization of an Engineered Src Kinase to Study Src Signaling and Biology.

Authors:  Leanna R Gentry; Andrei V Karginov; Klaus M Hahn; Channing J Der
Journal:  Methods Mol Biol       Date:  2016

8.  MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.

Authors:  Zhipeng Li; Xu Li; Chao Yu; Min Wang; Feng Peng; Jie Xiao; Rui Tian; Jianxin Jiang; Chengyi Sun
Journal:  Tumour Biol       Date:  2014-10-26

9.  MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1.

Authors:  Chao Yu; Min Wang; Zhipeng Li; Jie Xiao; Feng Peng; Xingjun Guo; Yazhu Deng; Jianxin Jiang; Chengyi Sun
Journal:  Cell Oncol (Dordr)       Date:  2015-02-10       Impact factor: 6.730

10.  Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity.

Authors:  Heike Döppler; Geou-Yarh Liou; Peter Storz
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.